Interleukin (IL)-17-producing T helper cells (T H 17) are a recently identified CD4 1 T cell subset distinct from T helper type 1 (T H 1) and T helper type 2 (T H 2) cells 1 . T H 17 cells can drive antigenspecific autoimmune diseases and are considered the main population of pathogenic T cells driving experimental autoimmune encephalomyelitis (EAE) 2 , the mouse model for multiple sclerosis. The factors that are needed for the generation of T H 17 cells have been well characterized [3] [4] [5] [6] . However, where and how the immune system controls T H 17 cells in vivo remains unclear. Here, by using a model of tolerance induced by CD3-specific antibody, a model of sepsis and influenza A viral infection (H1N1), we show that proinflammatory T H 17 cells can be redirected to and controlled in the small intestine. T H 17-specific IL-17A secretion induced expression of the chemokine CCL20 in the small intestine, facilitating the migration of these cells specifically to the small intestine via the CCR6/CCL20 axis. Moreover, we found that T H 17 cells are controlled by two different mechanisms in the small intestine: first, they are eliminated via the intestinal lumen; second, proinflammatory T H 17 cells simultaneously acquire a regulatory phenotype with in vitro and in vivo immune-suppressive properties (rT H 17) . These results identify mechanisms limiting T H 17 cell pathogenicity and implicate the gastrointestinal tract as a site for control of T H 17 cells.
T H 17 cells have been associated with the pathogenesis of several chronic inflammatory disorders, including rheumatoid arthritis and multiple sclerosis 2, 7 . To study the cellular and molecular mechanisms that control pathogenicity mediated by T H 17 cells we first used the CD3-specific antibody treatment model. It is known that CD3-specific antibody treatment induces a 'cytokine storm' and local inflammation mainly in the small intestine 8 . Despite this it has been validated as an in vivo model of tolerization 9 and is now under study in human clinical trials 10 . By mimicking antigen, CD3-specific antibody treatment leads to activation-induced cell death (AICD) of T cells 11, 12 and consequently a systemic upregulation of IL-6 (ref. 9 ) and transforming growth factor-b (TGF-b1) induced by phagocyte engulfment of apoptotic T cells 13 . In line with these publications, we found that CD3-specific antibody treatment induced an immunoregulatory environment marked by simultaneous expression of TGF-b1 and IL-6 ( Fig. 1a ). The combination of these cytokines is important for the development of T H 17 cells in vitro and in vivo as it has been previously clearly established 3, 4 . Accordingly, we found elevated levels of IL-17A in plasma of CD3-specific antibody-treated animals compared to controls ( Fig. 1a) .
First, we aimed to investigate the source of IL-17A. It has been reported that a few hours after injection of CD3-specific antibody, there is a rapid disappearance of the majority of T cells from the 1 Department of Immunobiology, Yale University School of Medicine, New Haven, Connecticut 06520, USA. 2 German Rheumatism Research Center (DRFZ), A Leibniz Institute, Berlin 10117, Germany. 3 Cluster of Excellence NeuroCure, Charite-Universitä tsmedizin Berlin, Berlin 10117, Germany. 4 13, 14 . Surprisingly, in parallel with the disappearance of T cells from the periphery, we found a concomitant increase in the percentage and the number of total T cells in the small intestine, in particular in the duodenum ( Supplementary Fig. 1a -c). In a newly generated IL-17A-eGFP knock-in mouse (enhanced green fluorescent protein was inserted in the Il17a locus; Methods and Supplementary  Fig. 2a-d and 3a-c) injected with CD3-specific antibody, 50-80% of the CD4 1 TCRb 1 T cells located in the duodenum were expressing IL-17A ( Fig. 1b and Supplementary Fig. 1d, e ). The percentage and number of T H 17 cells in the intestine decreased from the duodenum to the colon in a gradient-like fashion (Fig. 1b ). Detection of CD4 1 eGFP 1 T cells by immunofluorescence and two-photon-laserscanning microscopy confirmed the high frequency of T H 17 cells in the small intestine in situ ( Fig. 1c and Supplementary Fig. 4a-c) . Importantly, we also found T H 17 cell infiltration in the duodenum when animals were injected with a therapeutic non-FcR-binding CD3-specific antibody 15 , although the frequency and numbers of the T H 17 cells were lower compared to the FcR-binding antibody ( Supplementary Fig. 5a ). Similar results were observed after antigenspecific stimulation when soluble myelin oligodendrocyte glycoprotein antigen (MOG) was administered to MOG-TCR transgenic mice (2D2 mice) 16 ( Supplementary Fig. 5b ). Taken together these data suggest that the generation and the accumulation of T H 17 cells in the small intestine was not restricted to the CD3-specific antibody treatment, but was a general mechanism following strong T-cell receptor (TCR) stimulation.
We next wanted to identify the molecular signals important for the generation of T H 17 cells in vivo after CD3-specific antibody treatment. Because IL-6 is known to be important for T H 17 cell generation, we evaluated the importance of this cytokine. Il6 2/2 and wild-type mice were treated with CD3-specific antibody. In the Il6 2/2 mice, only a very small population of T H 17 cells (about 2%) could be found by flow cytometry in the small intestine ( Supplementary Fig. 6a ) and IL-17A was undetectable in the plasma (data not shown). To study the cellular source of IL-6, we treated mice with clodronate-loaded liposomes, which eliminates most macrophages and a significant proportion of dendritic cells compared to PBS-loaded liposomes 13 ( Supplementary  Fig. 6c ). IL-6 plasma levels were greatly reduced in mice treated with clodronate-loaded liposomes compared to control mice after CD3specific antibody injection ( Supplementary Fig. 6d ) and a profound reduction in T H 17 cells was observed ( Supplementary Fig. 6b , c). Taken together, these data support the notion that IL-6 secreted by antigen-presenting cells (APCs) is critical for the generation of T H 17 cells during CD3-specific antibody treatment.
We next analysed the mechanism leading to the specific accumulation of T H 17 cells in the small intestine, predominantly in the duodenum. T H 17 cells are known to express the chemokine receptor CCR6 (ref. 17) . Whereas CCR6 is relevant in different autoimmune disease models 7, 18 , the role of the CCR6/CCL20 axis in immune cell migration to the intestine during tolerance induction has not yet been evaluated. To study that, we analysed the expression of CCR6 on CD4 1 IL-17A-eGFP positive and negative cells ( Fig. 2a ) and Ccl20 mRNA expression ( Fig. 2b) in the spleen and the gut. CCR6 was mainly expressed in T H 17 cells from the spleen and the gut 24 h after CD3-specific antibody injection ( Fig. 2a ). Strikingly, when we performed a time course to measure the mRNA levels of Ccl20 in different parts of the intestine during CD3-specific antibody treatment, we observed that Ccl20 was expressed at the highest level in the duodenum in steady state conditions and was selectively further upregulated after CD3-specific antibody treatment (Fig. 2b, c and Supplementary Fig. 7) . To test the importance of the CCR6/CCL20 axis for the migration of T H 17 cells from the periphery to the duodenum, we treated Ccr6 2/2 and control mice with CD3-specific antibody. T H 17 cell number ( Fig. 2e ) and frequency ( Fig. 2d ) were strongly reduced in the intestine of the Ccr6 2/2 compared to wild-type mice. In general, we did not observe signs of intestinal inflammation in the Ccr6 2/2 mice as we did in wild-type controls after CD3-specific antibody treatment (data not shown). Interestingly, we detected a higher number of T H 17 cells in the spleen and lymph nodes of Ccr6 2/2 mice when compared to control animals ( Fig. 2e ). This increase was accompanied by splenomegaly and enlargement of lymph nodes (data not shown), indicating that CCR6 does not have a major role in the generation and expansion of T H 17 cells. In conclusion, CCR6 seems to be essential for the migration of T H 17 cells to the small intestine after CD3-specific antibody treatment, and the intestinal inflammation is dependent on this migration. Thus our data indicate that T H 17 cell migrate to the small intestine leading to intestinal inflammation and damage. However, we cannot exclude that a proliferation of gut resident T H 17 cells also contributes to the observed phenomenon.
To evaluate the contribution of IL-17A and IL-17F (T H 17 signature cytokines) in the induction of CCL20 expression in the duodenum, we treated Il17a 2/2 or Il17ra 2/2 mice with CD3-specific antibody. We found decreased levels of CCL20 in the Il17a 2/2 and the Il17ra 2/2 mice versus the controls after CD3-specific antibody treatment ( Fig. 2f ), indicating that IL-17 signalling has a major role in the induction of CCL20 in the duodenum. We next studied the cellular source of CCL20. Ccl20 mRNA was only detectable in the intestinal epithelial cells in untreated mice. Treatment with CD3-specific antibody led to a LETTER RESEARCH further upregulation of Ccl20 mRNA by the epithelial cells. Additionally, the CD4 1 T cells present in the small intestine after CD3-specific antibody treatment, most of which were T H 17 cells, expressed high levels of Ccl20 mRNA (Fig. 2g ). In conclusion, T H 17 cells via IL-17A and IL-17F production directly upregulate CCL20 production by the intestinal epithelial cells, which then leads to the subsequent recruitment of CCR6 1 T H 17 cells, which also produce CCL20. Of note, the intestinal inflammation after CD3-specific antibody treatment was transient and 100% of the mice recovered. To understand better the mechanisms underlying this process, we first assessed apoptosis of T H 17 cells in the small intestine but we did not detect a significant number of apoptotic cells (data not shown). When we studied the in vivo proliferation capacity of CD4 1 TCRb 1 T cells from the CD3-specific antibody-treated animals, we found that T H 17 cells from the duodenum were actively proliferating ( Supplementary Figs 8  and 9a , b). Using IL17A-eGFP 3 FoxP3-mRFP double reporter mice (monomeric red fluorescent protein was inserted in the foxp3 locus) we determined that CD4 1 IL-17A 1 T cells were proliferating at a higher rate than CD4 1 IL-17A 2 T cells in the duodenum (Supplementary Figs 8 and 9). Using two-photon laser-scanning microscopy, we found that the T H 17 cells in the duodenum did not show the typical behaviour of an apoptotic T cell, conversely, they behaved like activated T cells in terms of their pattern of speed and direction of migration (Supplementary Video). Taken together these data indicate that T H 17 cells do not die in the small intestine, but are rather actively proliferating.
In line with previous publications 8 we found that CD3-specific antibody treatment caused diarrhoea, oedema, inflammation and tissue destruction in the small intestine ( Supplementary Fig. 10a, b ), which correlated with the recruitment of T H 17 cells. However, the intestinal pathology was only transient and mice fully recovered. We therefore began to investigate the fate of T H 17 cells in the small intestine. Interestingly, we found a fraction of T H 17 cells in the intestinal lumen of the CD3-specific antibody-treated mice ( Supplementary Fig. 10c, d) . Given the severe inflammation, diarrhoea and tissue damage ( Supplementary Fig. 10a, b) , it is most likely that these cells were passively washed out, although an active mechanism cannot be excluded. Considering that the remaining T H 17 cells in the duodenum were actively proliferating, but the intestinal pathology was only transient, we were curious about the functional capabilities of these cells. Surprisingly, we found that the remaining T H 17 cells in the duodenum were able to suppress proliferation of responder T cells in vitro ( Fig. 3a) . To study the molecular properties of these suppressive T H 17 cells (which we refer from now on as rT H 17 cells), we performed a genome-wide transcriptional profiling assay (Fig. 3b) . We compared the gene expression pattern of rT H 17 cells from CD3-specific antibody-treated mice and genes expressed by pro-inflammatory T H 17 cells that were harvested from the central nervous system of EAE-induced mice. The signature genes of T H 17 cells, like Rorc, Rora, Il17a, Il22 or Il23r, were similarly expressed between both types of T H 17 cells. Also the activation status of these cells seemed to be similar, because activation markers such as CD69, CD25 and CD44 were equally expressed. However, we found that the rT H 17 cells from the CD3-specific antibody-treated mice showed a non-inflammatory gene expression profile compared to pro-inflammatory T H 17 cells isolated from the central nervous system of EAE-induced mice. Notably, the expression levels of Tnf-a and Il-2, two cytokines with clear pro-inflammatory roles 19, 20 , were greatly reduced in the rT H 17 cells from the small intestine. In contrast, these cells expressed high levels of IL-10, a cytokine with potent anti-inflammatory activities 21 ( Supplementary Fig. 11b and Fig. 3b ). These data are supported by a previous report showing that in-vitro-generated non-pathogenic T H 17 cells are able to express IL-10 (ref. 22) . To evaluate the molecular mechanisms involved in the suppressive function of the rT H 17 cells, different molecules were blocked in an in vitro suppression assay using monoclonal antibodies ( Supplementary Fig. 11a ). The suppressive capacity of the rT H 17 cells was partially dependent on IL-10, CTLA-4 and TGF-b. Blocking all three pathways resulted in a lack of suppression by the rT H 17 cells. T H 17 cells isolated from the spleen showed an intermediate phenotype. They exhibited a limited capacity to suppress the proliferation of T cells in vitro (Fig. 3a) , and also produced more TNF-a and IL-2, but less IL-10 compared to T H 17 cells isolated from the small intestine ( Supplementary Fig. 11b ). However, because some of the T H 17 cells in the small intestine downregulated CCR6 ( Fig. 2a) , it is possible that some rT H 17 might have migrated back from the small intestine to the spleen. If development of the suppressive capability occurred in the small intestine, then preventing the migration of the T H 17 cells to that site should prevent the development of these tolerogenic cells. To test this hypothesis, we analysed T H 17 cells isolated from the spleen of Ccr6 2/2 mice, because we showed already that these T H 17 cells are unable to migrate to the small intestine. Consistent with the hypothesis, Ccr6 2/2 T H 17 cells in the spleen showed high TNF-a production, failed to suppress T-cell proliferation in vitro, and were even proinflammatory, causing inflammatory bowel disease in vivo upon transfer into a lymphopenic host ( Supplementary  Fig. 12 a-d) . These data indicate that proinflammatory T H 17 cells do indeed acquire their suppressive phenotype in the small intestine.
To confirm our findings in an animal disease model, EAE-induced mice were treated with CD3-specific antibody. In line with a previous publication 23 we observed a protective effect when the treatment was administered during the course of the disease ( Supplementary Fig. 13a ). More importantly, we demonstrated that T H 17 cells were recruited to the duodenum of the CD3-specific antibody treated animals and these mice had strongly reduced numbers of T H 17 cells in the central nervous system (data not shown). Using a MOG-specific tetramer, we determined that a significant percentage of T H 17 cells in the duodenum were antigen-specific ( Supplementary Fig. 13b ), demonstrating that MOG-specific T H 17 cells were recruited to the duodenum following CD3-specific antibody treatment. In contrast the frequency IL10 IL17F 
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of MOG-tetramer-positive T H 17 cells was much lower in other organs of EAE-induced mice, which had not been treated with CD3-specific antibody (data not shown). This is evidence against a general increase in MOG-specific T H 17. Therefore our results show that antigenspecific T H 17 cells, with proinflammatory properties, generated in the periphery can be redirected to the small intestine. To confirm that rT H 17 cells isolated from the small intestine of CD3-specific antibodytreated mice are indeed in vivo immune-suppressive we tested their suppressive capacity in an EAE transfer model. We co-transferred MOG-specific in-vitro-differentiated T H 17 either alone or together with MOG-specific rT H 17 cells isolated from the small intestine of CD3-specific antibody-treated 2D2 transgenic mice. Strikingly, we found that rT H 17 cells were able to completely suppress the development of EAE in these transfer experiments ( Supplementary Fig. 13c, d) , indicating that the rT H 17 cells are indeed stable in terms of their immune suppressive function.
As mentioned above CD3-specific antibody treatment is already used in clinical trials 9,10 , and we therefore aimed to confirm our results using teplizumab (hOKT3c1(Ala-Ala)), one CD3-specific antibody used in these trials. To that end we used a humanized mouse system: we reconstituted Balb/c Rag-2 2/2 cc 2/2 double knockout mice with human peripheral blood mononuclear cells. Two weeks after the transfer we treated these mice with either OKT-3, an FcR-binding CD3-specific antibody used in the first human studies, or teplizumab, an FcR non-binding CD3-specific antibody. Strikingly, we found human T cells in the small intestine after treatment with both of these CD3-specific antibodies ( Supplementary Fig. 14a, b) . The presence of human IL-17A-, IL-10-and CCL20-producing cells in the small intestine in OKT-3-and teplizumab-treated mice was confirmed by realtime PCR ( Supplementary Fig. 14c ).
Taken together our results obtained in the CD3-specific antibody model suggest that T H 17 cells, by upregulating CCL20 expression in the duodenum via IL-17 signalling, have developed an elegant mechanism to limit the pathogenicity in order to avoid a life-threatening immune response. This predicted in turn that this mechanism should be general to most strong immune responses that result in T H 17 cells.
T H 17 cells have a crucial role in controlling different microorganisms in vivo 24 . We next investigated whether this mechanism of T H 17 cell control also functions during a strong immune response elicited by pathogenic microorganisms. We first used a murine model of sepsis. We injected Staphylococcus aureus, which is one of the most frequent organisms responsible for sepsis in humans 25, 26 , intravenously into IL-17A-eGFP reporter mice. Mice were analysed 3 days after the injection, at a time when they displayed severe clinical symptoms of sepsis (weight loss, dehydration, lethargy). Strikingly, we found the highest frequency and number of T H 17 in the small intestine ( Fig. 4a ). Interestingly, most T H 17 appeared to be TCR Vb8 1 . The injection of the superantigen SEB (Staphylococcus aureus enterotoxin B), which is produced by the bacteria used in these experiments and binds to Vb8 1 T cells, was sufficient to induce the accumulation of T H 17 in the small intestine just as in the anti-CD3 studies. As a control we injected mice with TSST-1 (toxic shock syndrome toxin 1), a superantigen that does not bind to Vb8 and is not produced by the bacteria we used. Of note, we observed that the administration of TSST-1 was less effective at inducing the accumulation of T H 17 cells in the small intestine ( Fig. 4b ). Finally, we could confirm that the T H 17 cells, induced by SEB treatment, expressed CCR6 and that CCL20 is specifically upregulated in the small intestine following SEB treatment (Fig. 4c) . Furthermore, while a subpopulation of the T H 17 cells was found in the intestinal lumen ( Supplementary Fig. 15 ), the remaining T H 17 cells demonstrated an immune-suppressive phenotype (Fig. 4d and Supplementary Fig. 16 ), again comparable to our results obtained in the CD3-specific antibody treatment. Interestingly, it is known that SEB can induce tolerance 27 , which is in line with our results that SEB leads to the generation of rT H 17 cells. Accordingly, we found that SEB and, to a lesser extent, TSST-1 treatment of EAE-induced mice led to the amelioration of disease (data not shown), which is in line with one previous publication 28 .
In addition to anti-bacterial immunity, viruses are the next key class of pathogens to which we must respond, yet contain excessive immunopathology which is commonly the cause of morbidity and mortality 29 . To address such an immune response, we analysed influenza, a viral infection that has devastated human populations. Notably, we again found increased T H 17 cell frequencies in the small intestine in mice infected with influenza A (H1N1) ( Supplementary Fig. 17 ).
In conclusion, we propose a general mechanism that could explain how a pro-inflammatory T H 17 immune response, which is beneficial in clearing infection, but immunopathogenic in excess, can be controlled by the mechanisms we describe here: namely by acquisition of an immune-suppressive phenotype or elimination into the intestinal lumen ( Supplementary Fig. 18 ). These findings and further studies aiming to identify the underlying mechanism of the conversion of pro-inflammatory T H 17 cells into rT H 17 cells may help in designing new strategies to control auto-reactive T H 17 cells in autoimmune diseases like multiple sclerosis.
METHODS SUMMARY
Anti-CD3, SEB, TSST-1 treatment and Staphylococcus aureus infection. Mice were injected intraperitoneally three times with either CD3-specific antibody 
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(clone 2C11, 20 mg per mouse) SEB (50 mg per mouse) or TSST-1 (50 mg per mouse) at 0, 48 and 96 h. Mice were analysed 100 h after the first injection, if not otherwise specified. Staphylococcus aureus was injected intravenously (1 3 10 8 colony-forming units per mouse) in order to induce sepsis. Mice were killed 3 days after the injection. Flow cytometric analysis. Cells were isolated from the organ as indicated. IL-17A-eGFP and CCR6 expression was assessed directly after isolation. When indicated cells were restimulated and intracellular cytokine staining for IL-17A was performed. Numbers in dot-plot quadrants indicate percent cells in each. Cells were gated on CD4 1 TCRb 1 events.
Real-time PCR. Ccl20 mRNA expression was measured in different tissues as indicated using real time PCR with reverse transcription.
In vitro suppression assay. Different suppressor cells were co-cultured with carboxyfluorescein diacetate succinimidyl ester (CFSE)-labelled CD4 1 CD25 2 responder T cells, which were isolated from the spleen of CD45.1 congenic mice. Bar represents undivided CFSE-labelled responder T cells.
METHODS
Mice. BALB/c mice (blastocyst donors), CD1 mice (foster mothers), Tet-Cre transgenic mice (''deletor'' mice, C57BL/6 background), C57BL/6 mice (B6), C57BL/6.Ly5.1 mice (CD45.1 1 ), IL6 2/2 mice and CCR6 2/2 mice were purchased from The Jackson Laboratories. MOG-transgenic mice (2D2 mice, C57BL/6 background) 30 and Foxp3 reporter mice (FIR mice, C57BL/6 background) 31 were intercrossed with the IL-17A-eGFP reporter mice. We also used Il17a 2/2 , Il17ra 2/2 and IL-10-eGFP mice (Tiger mice) [32] [33] [34] . All mice were kept under specific pathogenfree conditions in the animal care facility at Yale University. The mice were studied at 6-12 week of age. All the experiments were approved by the Institutional Animal Care and Use Committee of Yale University. For intracellular cytokine staining, the cells were restimulated with phorbol 12-myristate 13-acetate (PMA) (Sigma, 20 ng ml 21 ) and ionomycin (Sigma, 0.5 mg ml 21 ) for 4 h. Golgistop (BD Bioscience) was added during the last 3 h of restimulation. After restimulation, the cells were washed and a Ficoll gradient was performed. The cells were fixed with 1% paraformaldehyde (electron microscopy grade) for 10 min on ice. After two washes, cells were incubated with FITCconjugated anti-GFP antibody (Rockland) and phycoerythrin (PE)-conjugated anti-IL-17A (BD Bioscience) in wash/perm solution (BD Bioscience) for 30 min on ice. Cells were washed twice and resuspended in PBS. Acquisitions were made with a LSRII cytometer (BD Bioscience). For ex vivo-staining with MOG 38-49 /I-A(b)-tetramer-allophycocyanin (APC)labelled (mouse myelin oligodendrocyte glycoprotein 38-49, ''GWYRSPFSRWH'', NIH Tetramer Facility), single-cell suspensions were incubated at a density of 10 7 cells ml 21 with neuraminidase (0.7 mU ml 21 , neuraminidase type X from Clostridium perfringens, Sigma) in serum-free DMEM at 37 uC/10% CO 2 for 25 min before incubation with the I-A(b) multimers (30 mg ml 21 ) in DMEM supplemented with 2% FCS (pH 8.0) at room temperature for 4 h. After washing, cells were stained for 7-AAD (Molecular Probes), CD4 (RM4-5) and TCRb. hCLIP/I-A(b)-tetramer-APC-labelled was used as a control (''PVSKMRMATPLLMQA'', NIH Tetramer Facility). The percentage of tetramer cells was determined in the CD4/TCRb gate of live (7-AAD 2 ) cells. Stained cells were analysed on LSRII cytometer (BD Bioscience) and data were analysed with FlowJo software (Treestar). Flow cytometry and FACS sorting. Collected lymphocytes were treated with ammonium chloride lysis buffer (BioSource International) to remove red blood cells and washed with RPMI containing 10% FBS (Gemini Biological Products). Cells were then stained with a 1:400 dilution of the indicated antibodies together with 10 mg ml 21 anti-Fc-Receptor blocking antibody (2.4G2, American Type Culture Collection) in PBS containing 2% FBS and then washed twice with PBS. For isolating T cells, CD4 1 T cells were first enriched by magnetic-activated cell sorting beads (Miltenyi Biotec) and then stained with the indicated antibodies. The Becton Dickinson FACSVantage system and MoFlo sorter (DAKO Cytomation) were used for fluorescence detection and cell sorting. T H 17 differentiation in vitro. Splenocytes from IL-17A-IRES-eGFP mice and C57BL/6 mice were incubated with CD4-microbeads and then positively selected through LS columns (Miltenyi Biotec). After enrichment, naive cells (CD4 1 CD25 2 CD62L hi CD44 low ) were sorted by FACS as mentioned above. CD4 1 naive T cells were grown for 5 days at 10 6 cells ml 21 with plate-bound anti-CD3 (5 mg ml 21 ) and soluble anti-CD28 (2 mg ml 21 ) in medium (Bruff's medium supplemented with 10% FCS, L-glutamine, penicillin and streptomycin) under T H 17 conditions (TGF-b, IL-6, IL-23, anti-IFN-c, anti-IL4). IL-17A (eGFP) expression was determined by flow cytometry. Multiphoton imaging. The small intestine (duodenum) from an IL-17A-eGFP 3 Foxp3-mRFP double reporter mouse treated with CD3-specific antibody was mounted on a glass slide in a chamber consisting of a silicone isolator (20 mm diameter 3 0.5 mm, Electron Microscopy Sciences). The tissue was immersed in PBS and covered by a glass coverslip. An Olympus BX50WI microscope equipped with a 320x, numerical aperture 0.95 Olympus objective and a LaVision TriMScope Multiphoton System controlled by Imspector Software (LaVision Biotec) was used to collect images. For excitation, a Coherent Chameleon Ti:Sapphire laser was tuned to 960 nm. Images of 300 3 300 mm size were recorded at a resolution of 1,024 3 1,024 pixels with 1-mm z-spacing. Emitted light was collected with nondescanned detectors after having passed 435/90, 525/50 and 615/100 nm bandpass filters. Volocity software (Improvision) was used to create three-dimensional image stacks, and QuickTime Pro was used to generate image sequences.
In vivo T-cell stimulation and intestinal lymphocyte isolation. Different mice in C57BL/6 background were injected with anti-CD3 (20 mg, 145 2C11) 34, 35 intraperitoneally 1-3 times at an interval of 2 days between injections and killed 4 h after the final injection. For the controls, isotype control or PBS was injected. The intraepithelial lymphocytes (IEL) and lamina propria lymphocytes (LPL) were collected as described with some modifications 34 . In brief, small or large intestines were removed and Peyer's patches were dissected. The first 2 cm of the small intestine were considered as duodenum. Intestines were opened longitudinally and then were cut into strips 1 cm in length. Tissues were washed with Hank's buffered saline and incubated in the presence of 5 mM of EDTA at 37 uC for 30 min. The released cells were loaded onto a Percoll gradient and centrifuged. The cells between 40% and 100% Percoll were collected and used as intestinal epithelial lymphocytes. LPL were collected by digesting gut tissue, which was removed for IEL isolation as described above. The tissue was digested with collagenase IV (100 U, Sigma) at 37 uC for 1 h and loaded onto a Percoll gradient and centrifuged. The cells between 40% and 100% Percoll were collected and used as LPL.
For the lumen content isolation and analysis, mice were anesthetized using isoflurane. One ligation was made after the pylorus and a second one about 4-5 cm distal from the first ligation. A small incision without breaching the vessel proximal to the second ligation was made and 10 ml of pre-warmed PBS (2 ml min 21 ) was injected using a syringe and a 27G1/2 needle. The fluids were collected in a Petri dish placed under the incision proximal to the second ligation. The collected fluids were incubated for 15 min in HBSS/ EDTA and then filtered through a 70 mm cell strainer before FACS analysis. Adoptive transfer of CD4 1 T cells. CD4 1 FoxP3 1 and the CD4 1 FoxP3 2 T cells from the thymus or from the periphery of IL17A-eGFP 3 Foxp3-mRFP double reporter mice were collected and purified by magnetic-activated cell sorting (MACS; Miltenyi Biotec). After MACS enrichment, total CD4 1 Foxp3 1 and CD4 1 FoxP3 2 T cells were FACS-sorted and 4 3 10 6 T cells were adoptively transferred (intravenously) into sub-lethally irradiated, sex-matched wild-type CD45.1 1 recipient mice. Four weeks after transfer, animals were injected with CD3-specific antibody (20 mg) and the small intestines were recovered and examined for eGFP and mRFP by FACS. Immunofluorescence microscopy. Small intestines were removed from IL-17A-eGFP reporter mice and wild-type littermates after CD3-specific antibody treatment in vivo. Small intestines were fixed in 4% paraformaldehyde for 16 h. After two washes with PBS 20% sucrose solution was added. The 20% sucrose solution was replaced 16 h later with 30% sucrose solution. On the next day, the samples were washed and then snap-frozen in OCT and stored at 280 uC. Cryosections were cut at 12 mm on a Leica model CM1850 freezing microtome, applied to Superfrost Plus Gold slides (Fisher Scientific), air-dried, and PAP pen applied (Zymed Laboratories). Sections were blocked for 30 min at ambient temperature with serum-free protein block (Dako Cytomation) and were stained with PE-anti-CD4 (BD) and Alexa488-anti-GFP (Invitrogen) overnight at 4 uC. Samples were washed three times by immersing in PBS for 5 min and then mounted with Prolong gold mounting media with DAPI (Invitrogen). Sections were observed under dark field in independent fluorescence channels using an automated Olympus BX-61 microscope. Experimental autoimmune encephalomyelitis. Mice were immunized subcutaneously with 250 mg of MOG (Yale Keck facility) emulsified in CFA (BD Difco). Mice received 400 ng pertussis toxin (PTx, List Biological Laboratories) intraperitoneally at the time of immunization and 48 h later. Mice were checked for clinical symptoms daily, and signs were translated into clinical score as follows: 0, no detectable signs of EAE; 0.5, tail weakness; 1, complete tail paralysis; 2, partial hind limb paralysis; 2.5, unilateral complete hind limb paralysis; 3, complete LETTER RESEARCH
